Inhibitex, a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections, primarily focuses on the development of nucleotide/nucleoside analogs for the treatment of hepatitis C virus (HCV). Inhibitex was acquired in February 2012 by Bristol-Myers Squibb. It was the first life sciences company that spun out of Texas A&M to go public, and, in the process, the company raised $300 million.
